Therapeutic development of an NR1H3-targeting antisense oligonucleotide for ALS
Active Project Grant Awarded Last action
- Award ID
- HT9425261E084
- Recipient
-
Modulo Bio, Inc. UEI U1TNJGPGNHA9
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,739,076
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 25% complete
- Place of performance
- San Diego, CA 92121, USA
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded Modulo Bio, Inc. $1.739 million on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct therapeutic development of an NR1H3-targeting antisense oligonucleotide for amyotrophic lateral sclerosis (ALS). The award carries a period of performance through April 30, 2028, with all work performed at Modulo Bio's San Diego, California facility. This is a Project Grant, classified as assistance funding. An administrative modification corrected the payment office DODAAC code; no funds or terms were adjusted. Modulo Bio, a San Diego-based for-profit biotech firm, operates exclusively as a prime recipient on federal research grants and applies induced pluripotent stem cell-derived disease modeling, machine learning-driven target identification, and multi-omic analysis to develop therapeutic candidates for neurodegenerative disease.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $1,739,076 |
Quick answers
Who received award HT9425261E084?
HT9425261E084 was awarded to Modulo Bio, Inc. by Defense Health Agency (Department of Defense) on May 1, 2026.
How much is award HT9425261E084 worth?
$1,739,076 has been obligated on HT9425261E084.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award